X

Trial Profile

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs H3B 6527 (Primary)
Indications Cholangiocarcinoma; Liver cancer
Focus Adverse reactions
Sponsors H3 Biomedicine

Most Recent Events

05 Apr 2022 Status changed from active, no longer recruiting to completed.
11 Jan 2022 Planned End Date changed from 31 Dec 2021 to 28 Feb 2022.
11 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 28 Feb 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com